Effect of administration of interferon alfa 2-b in treatment of pterygium

Intralesional administration of interferon alfa 2-b in treatment of pterygium

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120817010617N5

Enrollment

Registered

2020-04-14

Start date

2020-01-21

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pterygium of eye. Pterygium of eye

Interventions

Intervention 1: Intervention group: 0.1 ml interferon a-2b (IFN-a-2b) IntronA, Schering Plough, Kenilworth, NJ1 million units/mL) will be injected in the pterygium base near the Limbus area. then chl

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with pure Pterygium that involve at least 1mm cornea based on clinical diagnosis

Exclusion criteria

Exclusion criteria: Any eye pathology other than pterygium

Design outcomes

Primary

Measure	Time frame
Pterygium size. Timepoint: Patients will be examined after 48 hours, one week, and then monthly for 6 months after injection. Method of measurement: Based on slit lamp examination.;Photophobia. Timepoint: Patients will be examined after 48 hours, one week, and then monthly for 6 months after injection. Method of measurement: Based on slit lamp examination.;Pterygium Hyperemia. Timepoint: Patients will be examined after 48 hours, one week, and then monthly for 6 months after injection. Method of measurement: slit lamp examination.	—

Measure

Time frame

Pterygium size. Timepoint: Patients will be examined after 48 hours, one week, and then monthly for 6 months after injection. Method of measurement: Based on slit lamp examination.;Photophobia. Timepoint: Patients will be examined after 48 hours, one week, and then monthly for 6 months after injection. Method of measurement: Based on slit lamp examination.;Pterygium Hyperemia. Timepoint: Patients will be examined after 48 hours, one week, and then monthly for 6 months after injection. Method of measurement: slit lamp examination.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMeisam Sargazi

Zahedan University of Medical Sciences

Meisam.sargazi@gmail.com+98 54 3329 5796

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026